Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
about
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeEpigenomics of leukemia: from mechanisms to therapeutic applicationsNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeClinical Results of Hypomethylating Agents in AML TreatmentSuccessful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.Hypomethylating agents and other novel strategies in myelodysplastic syndromes.Demethylating agents in myeloid malignancies.Azacitidine in the management of patients with myelodysplastic syndromes.Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Novel postremission strategies in adults with acute myeloid leukemia.Role of epigenetic therapy in myelodysplastic syndrome.Epigenetic regulation in myelodysplastic syndromes: implications for therapy.Hypomethylating agents for urologic cancers.5-Azacytidine for the treatment of myelodysplastic syndromes.Stopping higher-risk myelodysplastic syndrome in its tracks.Epigenetics in the hematologic malignancies.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.Clofarabine desensitization: A case report: Leukemia research reports.Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.Prognostic impact of p15 gene aberrations in acute leukemia.DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
P2860
Q24632949-926E20BE-1E8B-43EB-9013-8E464D39EF10Q26823403-A705CBF5-AC74-4D87-B098-078EF9B7C64DQ26829132-46D4C5BA-D0EE-4B58-8290-14629E207D83Q27022725-74D14D5C-BD26-4375-8A9D-2FD2713AC38BQ32182249-C664800A-8D2C-4167-83AB-0C0C59B7F03FQ33412609-DF1BF3DE-016D-4777-BF80-44508D51F7C9Q33423753-9B59A191-B887-43E2-BEC4-E3BE1C2BEEB5Q34172912-7EF2B3B9-36ED-4D8A-A75F-2513537F076DQ34667051-1E03FAC0-F6C8-4FBB-85C5-E850168EBE31Q34847863-2D974DCC-39F7-49B4-9E2E-67CCD9497793Q36768610-61158EA2-D161-4FF6-ACB0-D8CBB44D19FDQ36934199-53C9E142-4D65-48F8-A614-6173FD10E087Q37495378-08AF1421-432A-4203-9EDA-3478F5CBA617Q37810062-8F54F501-1D55-4B16-87A9-F30158F79889Q37850456-D465E27F-BDA1-4768-AB3F-20DA0F42657FQ37854737-BB853584-6F77-4631-84C5-269BC93A46B4Q38102062-18391BFC-596D-4722-A562-F8F93AAACF7FQ38248180-05325598-6816-47B2-AA78-BF4FE8DFEA3AQ38282809-3DFBB456-C886-4C7B-AADE-6AC2853D26EDQ38918850-42E5CD0E-8459-4551-B6C5-6B15A8BA46D6Q41509184-75ACAF9E-9E53-47F5-B3F1-33C6DF97C93FQ42268932-A5E3250D-4914-4355-83D9-FE3371CEE402Q43577534-17694978-D6E3-443E-B12B-170D91228A8FQ47411837-A1AD231C-3003-4F22-B034-8623E9263C6BQ53830978-D9CC15DC-5458-4449-9273-766E4930A297
P2860
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Maintenance treatment with aza ...... after induction chemotherapy.
@ast
Maintenance treatment with aza ...... after induction chemotherapy.
@en
type
label
Maintenance treatment with aza ...... after induction chemotherapy.
@ast
Maintenance treatment with aza ...... after induction chemotherapy.
@en
prefLabel
Maintenance treatment with aza ...... after induction chemotherapy.
@ast
Maintenance treatment with aza ...... after induction chemotherapy.
@en
P2093
P50
P1476
Maintenance treatment with aza ...... after induction chemotherapy.
@en
P2093
Anna Olsson
Anna Porwit
Eva Hellström-Lindberg
Gunnar Oberg
Jan Astermark
Jon M Tangen
Jonas Wallvik
Lars Kjeldsen
Lars Nilsson
Lena-Maria Engström
P304
P356
10.1111/J.1365-2141.2010.08235.X
P407
P577
2010-05-20T00:00:00Z